INTRODUCTION
HIV-1 infection can be suppressed with combination antiretroviral therapy (ART). However, therapy must be maintained for the life of the individual because even years of ART does not eliminate a reservoir of latently infected cells harboring replication-competent provirus (Siliciano et al., 2003) . As a result, ART interruption produces rapid viral rebound (Davey et al., 1999) . One strategy proposed to eliminate latent viruses involves reversing their latent state using agents that induce HIV-1 RNA synthesis under the cover of ART (Deeks, 2012) . However, all attempts to alter the reservoir by intensifying ART with additional antiretroviral drugs (Dinoso et al., 2009; Gandhi et al., 2010) or by administering viral inducers in the presence of ART have failed to date (Archin et al., 2014; Dybul et al., 2002; Lafeuillade et al., 2001; Prins et al., 1999) .
Like ART, broadly neutralizing antibodies (bNAbs) against HIV-1 can completely suppress viremia in HIV-1-infected humanized mice (hu-mice) (Horwitz et al., 2013; Klein et al., 2012b) and SHIV-infected macaques (Barouch et al., 2013; Shingai et al., 2013) . Although the composition of the reservoir is ill defined and may differ between ART and antibody treatments, discontinuation of ART or bNAb therapy in hu-mice and macaques results in viral rebound, indicating persistence of a functionally silent pool of cells harboring replication-competent virus. Moreover, the relative frequency of latently infected CD4 + T cells as measured by ex vivo reactivation is similar in ART-suppressed hu-mice and humans (Chun et al., 1997; Denton et al., 2012; Finzi et al., 1997; Marsden et al., 2012; Wong et al., 1997) . Thus, antibodies and ART control HIV-1 infection in hu-mice but allow persistence of a latent reservoir. Unlike ART, however, antibodies can engage the host immune system by virtue of their Fc effector domains (Nimmerjahn and Ravetch, 2008) and thereby accelerate clearance of cell-free virus (Igarashi et al., 1999) , induce antibody-dependent cytotoxicity to kill infected cells (Bonsignori et al., 2012; Chung et al., 2011; Forthal et al., 2013; Forthal et al., 2001; Jost and Altfeld, 2013; Sun et al., 2011) , and produce immune complexes that activate dendritic cells to become potent antigen-presenting cells (Dhodapkar et al., 2005) . Finally, some classes of bNAbs can prevent cell-cell transmission of HIV-1 (Abela et al., 2012; Malbec et al., 2013) , whereas ART's activity in this regard is still debated (Agosto et al., 2014; Schiffner et al., 2013; Sigal et al., 2011) .
Here, we examine the effects of bNAbs on the establishment of the reservoir and on its maintenance in the presence of inducers of viral transcription by measuring viral rebound. We find that bNAbs can interfere with the establishment of the reservoir by a mechanism that depends on their ability to bind to Fc receptors and that bNAbs plus a combination of inducers can reduce viral rebound from the reservoir in established infections in hu-mice.
RESULTS

Postexposure Prophylaxis with bNAbs
The ART-resistant reservoir is established early in infection, as evidenced by postexposure prophylaxis experiments in humans and macaques (Landovitz and Curry, 2009; Lifson et al., 2000; Tsai et al., 1998; Tsai et al., 1995; Whitney et al., 2014) . Postexposure prophylaxis with ART or previous-generation bNAbs is only effective when administered within 24 hr of intravenous exposure (Ferrantelli et al., 2007; Landovitz and Curry, 2009; Lifson et al., 2000; Nishimura et al., 2003; Tsai et al., 1995 Tsai et al., , 1998 . To determine whether the current generation of more potent bNAbs can abort the establishment of a latent HIV-1 reservoir at later time points, we performed postexposure prophylaxis experiments in hu-mice ( Figure 1A ). Mice were infected with HIV-1 YU2 (150 ng p24) by intraperitoneal injection and were treated with either ART (raltegravir, emtricitabine, tenofovir) (Denton et al., 2012; Nischang et al., 2012) or a tri-mix of bNAbs (3BNC117, 10-1074, and PG16) (Horwitz et al., 2013) 4 or 8 days after infection, when viremia was already detectable in 51 of 70 mice. Plasma viremia varied from undetectable to 2.70 3 10 6 viral RNA copies/ml at 4 days after infection ( Figures 1B-1E and Data S1 available online). In the absence of therapy, 14 out of 15 mice in the control group developed sustained plasma viremia, ranging from 2.48 3 10 3 to 4.19 3 10 6 copies/ml ( Figure 1B) . Doses of ART and antibodies were chosen on the basis of their therapeutic efficacy in chronic HIV-1 infection in hu-mice (Denton et al., 2012; Horwitz et al., 2013; Klein et al., 2012b; Nischang et al., 2012) . ART was administered in the food for up to 40 days, starting 4 days after infection (Denton et al., 2012; Nischang et al., 2012) . Antibodies were administered subcutaneously with a loading dose of 3 mg per mouse and three to five subsequent doses of 1.5 mg each, spaced 3-4 days apart ( Figure 1A ). Consistent with human and macaque studies, 18 of 22 mice treated with ART showed viremia after ART termination, demonstrating that this form of therapy is relatively ineffective at preventing reservoir development in hu-mice when administered 4 days after infection ( Figure 1C ). Among the 18 viremic mice, viremia was first detected 28-84 days after ART termination (Figures 1C and S1) . In contrast, 10 of 21 hu-mice treated with antibodies 4 days after infection showed viremia by the terminal point (p = 0.027, Figure 1F ), and for 9 of these 10 viremic mice, the first detectable viremia occurred 74-107 days after the last antibody injection ( Figures 1D and S1 and Data S1A). The delay in viral rebound observed for mice treated with antibody at day 4 was statistically significant compared to ART-treated mice (Figure S1 ). The mice that rebounded showed a geometric mean antibody concentration at rebound of 0.46 mg/ml. However, sustained inhibitory antibody levels did not account for the 11 mice that did not rebound, all of which had antibody levels % 0.50 mg/ml by termination (Data S1C). In contrast to bNAb treatment at day 4, bNAb treatment after 8 days was far less effective, resulting in viremia in 10 of the 11 treated mice 44-58 days after the last antibody injection (Figures 1E and 1F and Data S1B) .
Mice in the early treatment group that failed to show detectable plasma viremia were further examined for the presence of human CD4
+ T cells and cell-associated HIV-1 RNA and DNA in the spleen. We found that mice that failed to develop sustained plasma viremia had similar percentages of CD4 + T cells relative to infected controls, which correlated with absolute CD4 + T cell levels ( Figures 1G and S2) . Therefore, differences in CD4 + T cell levels are unlikely to account for the observed differences between viremic and aviremic mice ( Figure 1G ). Moreover, T-cell-associated HIV-1 RNA levels were consistent with plasma viral loads, with mice that remained aviremic having either undetectable or lower cell-associated HIV-1 RNA than mice that developed sustained viremia ( Figure 1H ).
We measured cell-associated viral DNA as an imperfect surrogate of the HIV-1 reservoir. HIV-1 DNA is thought to overestimate the reservoir because it fails to exclude damaged or incomplete viral sequences that cannot be reactivated (Ho et al., 2013) . In addition, the overall number of cells assayed in mice is limited and therefore the assay is not very sensitive. Nevertheless, we found HIV-1 DNA measurements to be consistent with each mouse's rebound status ( Figure 1I ). We conclude that bNAbs can interfere with the establishment of the latent HIV-1 reservoir in hu-mice, as determined by the significant delay in viral rebound.
Fc Receptor Binding Is Required for bNAb Activity
To determine whether the efficacy of bNAbs is dependent on the antibodies' ability to engage components of the immune system through their Fc domains, we repeated the day 4 postexposure prophylaxis experiments using the same tri-mix of bNAbs carrying Fc region mutations that abrogate both human and mouse Fc-receptor binding (G236R/L328R; GRLR, herein referred to as FcR null ) (Horton et al., 2010) . Despite equivalent neutralizing activity in TZM-bl assays (Pietzsch et al., 2012) , FcR null antibodies were far less potent than controls in vivo ( Figure 2 and Data S2). Mice treated with FcR null tri-mix initially suppressed viremia at the same rate as the wild-type antibodytreated mice (Figure 2A ). However, 9 of 15 mice receiving postexposure prophylaxis with the FcR null tri-mix showed viral rebound by 44 days after the last antibody injection. In contrast, 44 days after the last injection of control antibodies, only 1 of 21 mice showed rebound viremia (p = 0.0004). Not only was the delay in viral rebound significantly reduced for FcR null antibodies, but the antibody levels at the time of viral rebound were $50-fold higher for mice receiving FcR null trimix compared to wild-type tri-mix (p = 0.0007, Figure 2B ). This suggests that FcR null antibodies have reduced activity in vivo, and thus Fc function enhances antibody activity but is not an absolute requirement. The escape variants to the individual bNAbs in the tri-mix used in these experiments have been documented extensively (Horwitz et al., 2013; Klein et al., 2012b) . However, we have never observed HIV-1 escape by mutation to the bNAb trimix. Rather, viral rebound is usually due to a drop in antibody concentrations to subtherapeutic levels (Horwitz et al., 2013; Klein et al., 2012b) . Because mice receiving FcR null tri-mix showed viral rebound in the presence of antibody concentrations far higher than the therapeutic threshold for wild-type antibodies ( Figure 2B ), we cloned and sequenced gp120 from the 9 mice that rebounded by day 44 to examine the mechanism for viral breakthrough in the presence of FcR null tri-mix ( Figure 2C (H) Cell-associated HIV-1 RNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 RNA to CCR5 copies for each mouse. Gray shading indicates the detection limit of 1.25 3 10 À5 copies per cell.
(I) Cell-associated HIV-1 DNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 DNA to CCR5 copies for each mouse. Gray shading indicates the detection limit of 2.0 3 10 À5 copies per cell.
Mice that died prematurely are not included in Figures 1G-1I . See also Figures S1, S2, and Data S1.
Combination Therapy with bNAbs and Inducers
A small number ($15%) of chronically infected hu-mice and macaques treated with antibodies fail to show rebound viremia after therapy is discontinued (Barouch et al., 2013; Horwitz et al., 2013; Klein et al., 2012a; Shingai et al., 2013) . This suggests that antibodies may be able to decrease the size of the reservoir or interfere with its maintenance in established infections. To determine whether agents that induce viral transcription from latently infected cells can enhance this effect, we combined antibody therapy with viral inducers (Figure 3 and Data S3). Hu-mice with established HIV-1 YU2 infections (viremia ranging from 4.70 3 10 3 -7.96 3 10 5 copies/ml at 2-3 weeks after infection; Figures 3B-3E) were treated with tri-mix bNAbs. When plasma viremia and cell-associated HIV RNA dropped below detection, they were co-administered a viral inducer for 5-14 days and monitored for viral rebound for an additional 47-85 days (Figures 3B-3E and S3). The inducers tested were vorinostat, an HDAC inhibitor (Archin et al., 2009a; Archin et al., 2009b; Contreras et al., 2009 ); I-BET151, a BET protein inhibitor (Boehm et al., 2013b; Dawson et al., 2011) ; and CTLA, a T cell inhibitory pathway blocker (Alegre et al., 2001; Krummel and Allison, 1995) . They were selected because of their documented abilities to induce HIV-1 transcription in vitro, as well as their safety and established pharmacokinetic properties in mice (Krejsgaard et al., 2010; Kwon et al., 1997; Nicodeme et al., 2010) .
Hu-mice receiving antibodies plus vorinostat showed no significant differences in viral rebound compared to hu-mice receiving antibody alone (Figures 3B and 3C and Data S3) . The same result was seen for hu-mice treated with antibodies plus I-BET151 or CTLA ( Figures 3D and 3E and Data S3). All 10 mice that received antibody therapy plus vorinostat showed viral rebound when the antibody dropped below therapeutic levels. Of 12 mice that received antibody therapy plus I-BET151, 11 had viral rebound, and 10 of 11 mice that received antibody plus CTLA showed viral rebound. In total, of 33 mice that received antibody plus a single inducer, 31 showed viral rebound. In comparison, of 25 mice that received antibody therapy alone, 22 rebounded after the level of passively administered antibody decayed below the therapeutic threshold (p = 0.64, Fisher's exact test).
To determine whether a combination of inducers might be more effective than a single inducer, we administered all three inducers simultaneously (Figure 4 and Data S4). In the absence of antibody therapy, the combination of all three inducers did not alter the human graft and did not abort or noticeably alter active infection ( Figure S4 ). Additionally, the human graft did not differ between groups of mice that received antibody alone versus antibody plus the combination of inducers ( Figure S4 ). 23 mice that initially suppressed viremia on antibody therapy were treated with the inducers combination and followed for 62-105 days after the last antibody injection ( Figure 4A ). Only 10 of the 23 mice (43%) showed viral rebound, and the remaining 57% of mice failed to rebound, a significant decrease in rebound frequency compared to antibody alone (p = 0.0018, Fisher's exact test) or to antibody plus a single inducer (p = 0.0001, Fisher's exact test) ( Figures 4B and S5) .
Importantly, when compared to antibody alone, neither single inducers nor combination inducers measurably altered the frequency of CD4 + T cells remaining at the end of the experiment ( Figure 5A ). Additionally, cell-associated viral RNA measured in splenic T cells at the terminal point supported the results from the plasma viremia levels, with mice that failed to show viral rebound in the plasma also having undetectable cell-associated viral RNA ( Figure 5B ). Finally, when compared to controls, hu-mice that failed to rebound after combination antibody and inducer therapy showed similar initial plasma viremias to mice that rebounded across all experimental groups ( Figure 5C ). Therefore, neither initial viremia levels nor CD4 + T cell levels can account for the differences between the experimental groups. To determine whether antibody persistence or premature termination accounted for differing viral rebound outcomes, we calculated antibody levels at the time of rebound and at the terminal point for 59 of the 63 rebounding mice. The average plasma antibody concentration at the time of viral rebound was 2.97 mg/ml ( Figure 5D ). Because the antibody concentrations decayed to 2.97 mg/ml at different rates in individual mice, we calculated the number of days that elapsed from when each individual mouse's antibody levels reached 2.97 mg/ml to when the mouse showed rebound viremia. Of 59 mice, 50 rebounded within 10 days ( Figure 5E ). Of the 18 nonrebounding mice, the average antibody concentration at the terminal point was 0.44 mg/ml, with 15 out of 18 mice having antibody concentrations <2.97 mg/ml. Furthermore, in nonrebounding mice, an average of 20.2 days elapsed from the time antibody concentrations reached 2.97 mg/ml to termination ( Figure 5F ). Thus, failure to rebound cannot be explained by antibody persistence or premature termination.
Finally, we could not detect viral DNA at the terminal point in the majority of mice that did not rebound, whereas the majority of mice that did rebound had detectable HIV-1 DNA, with an average of 0.09 copies per T cell (Figure 5G) . We conclude that combining vorinostat, I-BET151, and CTLA with immunotherapy decreases the frequency of viral rebound in hu-mice.
DISCUSSION
Eliminating the HIV-1 reservoir in chronic infection is essential to curing the disease, but direct measurement of the latent reservoir to evaluate therapeutic eradication strategies remains difficult . Quantitative viral outgrowth assays and PCR-based assays of integrated DNA yield disparate results (Eriksson et al., 2013) , in part because PCR cannot distinguish between inactive and permanently disabled proviruses, whereas outgrowth assays underestimate reservoir size (Ho et al., 2013) . Indeed, the best way to determine whether a persistent reservoir exists is to measure viral rebound after discontinuing therapy in vivo.
Because the precise cellular and molecular nature of the HIV-1 reservoir is debated, it is not possible to know with certainty how its composition might differ between humans, macaques, and hu-mice. Hu-mice resemble infected humans in that they contain human cells that are infected with authentic HIV-1 (Brehm et al., 2014; Hatziioannou and Evans, 2012) . In addition, the kinetics of viral rebound in hu-mice after suppression of viremia with ART resembles infected humans (Horwitz et al., 2013; Nischang et al., 2012) . However, human hematopoietic reconstitution in mice is incomplete; thus, important cellular elements of the reservoir may be absent in hu-mice. Additionally, the human graft and the infection can only be maintained in mice for a limited time, making it impossible to distinguish between integrated and unintegrated forms of HIV-1 latency (Bukrinsky et al., 1991) .
The macaque model is valuable because it represents an immunologically intact host that may harbor reservoirs found in humans, but not in mice. However, the infection in macaques involves nonhuman primate cells with SHIV or SIV, which differ significantly from HIV-1 molecularly and in their response to drug therapy. Thus, neither of the two model systems is entirely faithful to the human infection. Nevertheless, the two models have produced very similar results in both immunotherapy and prevention experiments to date (West et al., 2014) . Whether our results with inducers will translate to infected humans can only be determined in clinical studies.
Despite the potential differences between available models, our experiments indicate that bNAbs can interfere with the establishment of the reservoir in humanized mice when administered early in the infection. One of the key differences between antibodies and ART is that antibodies can engage a variety of host immune effector pathways by way of their Fc receptors (Nimmerjahn and Ravetch, 2008) . Consistent with this important difference, our experiments show that the mechanism by which antibodies suppress active infection is dependent on their ability to engage components of the immune system by binding to Fc receptors. Engagement of these receptors is also implicated in antibody-mediated protection against infection in mice and macaques (Hessell et al., 2007; Pietzsch et al., 2012) . However, in contrast to the relatively modest effect of FcR engagement on prophylaxis against initial infection (Hessell et al., 2007; Pietzsch et al., 2012) , the $50-fold effect on the dose of antibody required to suppress viral rebound after early therapy is impressive. One potential explanation for the difference in relative antibody potency for prevention versus suppression of rebound viremia is that the effects on the latter are compounded over a far longer period of antibody therapy (McMichael et al., 2010) .
One of the strategies proposed to eliminate latent viruses involves inducing their expression under the cover of ART. In theory, this would kill actively infected cells while preventing the spread of infection (Deeks, 2012) . In vitro experiments indicate that silent proviruses can, in fact, be induced to become active by a variety of different agents that impact viral transcription (Bullen et al., 2014; Ho et al., 2013) . However, whether reactivated cells will die by the cytopathic effect in the presence of ART has recently been called into question (Shan et al., 2012) . Of the three inducers that we tested, vorinostat is the only one that has been studied in HIV-1-infected humans for this purpose. Infected individuals treated with vorinostat plus ART showed a transient increase in resting CD4 + T cell-associated HIV-1 RNA but no change in plasma viremia or in the frequency of replication-competent HIV-1 within resting CD4 + T cells (Archin et al., 2014; Archin et al., 2012) . Our results in hu-mice are consistent with the human studies and extend them to additional candidate inducers, demonstrating that administration of a single inducer has no significant effect on the ability of the latent reservoir to produce rebound viremia. Although we could not detect an increase in viremia following administration of either single or combination inducers, antibodies were still present and may have interfered with our ability to detect the virus (Igarashi et al., 1999) .
Antibody and inducer combinations have not been optimized, and we cannot explain why 43% of mice receiving antibodies plus combination inducers continue to rebound. Nor have we addressed the mechanism that would explain the difference between single and combination inducers. However, experiments using cell lines that contain artificial indicators of HIV-1 latency indicate that HDAC and BET protein inhibitors show synergy with transcriptional activators in reactivating HIV-1 in vitro (Boehm et al., 2013a; Dar et al., 2014; Quivy et al., 2002; Reuse et al., 2009) . Consistent with the in vitro experiments, the combination of inducers appears to be synergistic in vivo because single inducers had no measurable effect above the background controls, whereas $57% of the hu-mice treated with antibodies plus combination inducers failed to rebound. Irrespective of the mechanism, the reduction in viral rebound suggests that the reservoir of HIV-1-infected cells remaining after combination inducer and antibody therapy in hu-mice is significantly decreased, establishing the principle that the HIV-1 reservoir can be altered by combination therapy with antibodies and inducers in vivo. 
Humanized Mice
Humanized mice were generated as previously described (Klein et al., 2012b) . In brief, human fetal livers were obtained from Advanced Bioscience Resources (ABR). Fetal livers were homogenized and incubated in HBSS media with 0.1% collagenase IV (Sigma-Aldrich), 40 mM HEPES, 2 mM CaCl 2 , and 2 U ml À1 DNAase I (Roche) for 30 min at 37 C. Hematopoietic stem cells (HSCs) were isolated from digested liver using CD34 + HSC isolation kit (Stem Cell Technologies). Neonatal NRG mice (1-5 days old) were sublethally irradiated with 100 cG and injected intrahepatically with 2 3 10 5 human CD34 + HSCs 6 hr after irradiation.
Mouse Screening for Humanization
Eight or more weeks after HSC injection, mice were screened for the presence of human lymphocytes in peripheral blood by flow cytometry. 200 ml whole blood was collected by facial vein bleed and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Life Sciences). PBMCs were stained with antibodies to mouse CD45-PECy7, human CD45-Pacific Orange, human CD3-Pacific Blue, human CD19-APC, human CD4-PE, human CD8-FITC, and human CD16-Alexa700 for 25 min at 4 C. Cells were washed and fixed using Cytofix/Cytoperm (BD Biosciences (C) Plasma viremia before therapy was initiated for each mouse. There was no significant difference for any individual group (Kruskal-Wallis test).
(D) The plasma antibody level (mg/ml) at the time of viral rebound for each mouse that rebounded, organized by treatment group. The mean plasma antibody level at the time of rebound was 2.97 mg/ml for all groups.
(E) For each mouse that rebounded, the number of days that elapsed from when the antibody level dropped below 2.97 mg/ml to the time of rebound. (F) For mice that did not rebound, the number of days that elapsed from when each mouse's antibody levels dropped below 2.97 mg/ml to the terminal point.
(G) Cell-associated HIV-1 DNA measured in spleen T cells at the terminal point, plotted as the ratio of HIV-1 DNA to CCR5 copies for each mouse. Mice that had measureable HIV-1 DNA but undetectable CCR5 DNA are plotted as 10 4 copies per cell.
Mice that died prematurely are not included in Figures 5A , 5B, and 5G.
viremia was measured at 72-96 hr following the first HIV-1 YU2 injection, and treatment was initiated 4 days following the first injection. For experiments assessing the effects of bNAbs and inducers on established infections, mice with measurable human CD4 + cells by FACS were injected with two doses of HIV-1 YU2 (150 ng p24), and pre-treatment viremia was measured 14-20 days after the first injection. Mice with plasma viral loads >3,000 RNA copies/ml were selected to receive antibody therapy. After five subcutaneous antibody injections (see below), posttreatment viremias were measured. Only mice with completely suppressed plasma viremias were selected for further analysis and to receive viral inducers.
Plasma Viral Load Measurements 300-500 ml of whole blood was collected from mice at each time point by facial vein bleed. Whole blood was spun at 300 3 g for 10 min to separate plasma from the cellular fraction. Total RNA was extracted from 100 ml plasma using QIAmp MinElute Virus Spin Kit (QIAGEN) in combination with RNase-free DNase (QIAGEN), eluted in a 50 ml volume. HIV-1 RNA was quantified by qRT-PCR. The reaction mixture was prepared using TaqMan (Ct) values were calibrated using standard samples with known amounts of absolute viral RNA copies. The quantitation limit was previously determined to be 800 copies/ml (Klein et al., 2012b) .
Gp120 Sequencing
Gp120 cloning and sequencing was performed as previously described (Klein et al., 2012a) . In brief, cDNA was synthesized from viral RNA using SuperScript III reverse transcriptase (Invitrogen Life Technologies). cDNA was amplified with Expand Long Template PCR System (Roche) with nested PCR. Primers for the first round of PCR were 5 0 -GGCTTAGGCATCTCCTATGGCAGGAA GAA-3 0 and 5 0 -GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-3 0 .
Primers for the second round of PCR were 5 0 -TAGAAAGAGCAGAAGACA GTGGCAATGA-3 0 and 5 0 -TCATCAATGGTGGTGATGATGATGTTTTTCTCTC TGCACCACTCTTCT-3 0 . Gel-purified PCR amplicons were ligated into pCR4-TOPO (Invitrogen) and transformed into One Shot TOP10 cells. Individual colonies were sequenced using M13F and M13R primers. Sequences were aligned to gp120 YU2 (accession number M93258) and analyzed for mutations using Los Alamos Highlighter tool (http://www.hiv.lanl.gov/content/sequence/ HIGHLIGHT/HIGHLIGHT_XYPLOT/highlighter.html).
Cell-Associated HIV-1 RNA The cellular fraction of whole blood was resuspended in 400 ml PBS, and PBMCs were isolated by density gradient centrifugation as described above. Lymphocytes were split into two samples, one for cell-associated HIV-1 RNA measurements and one for cell-associated HIV-1 DNA measurements. Cellassociated RNA was extracted and quantified by the same procedures as described above for plasma viral RNA. The lower limit of detection was determined to be ten copies of viral RNA per qRT-PCR reaction. Cell-associated HIV-1 RNA is reported as the ratio of HIV-1 RNA copies per sample to CCR5 genomic DNA copies per equivalent sample measured in DNA extract. For terminal point measurements, spleen tissue was isolated, homogenized, and filtered through 40 mm mesh. Splenocytes were used to isolate HIV-1 RNA as described above.
Cell-Associated HIV-1 DNA PBMCs were isolated from whole blood as described above. Splenocytes were isolated from spleen as described above. Total DNA was extracted using QIAmp DNA Blood Mini Kit (QIAGEN) and eluted in 80 ml volume. Purified DNA was quantified for HIV-1 DNA by qPCR using the primers and probe for HIV-1 RNA quantification mentioned above. Genomic human CCR5 DNA was quantified with primers 5 0 -GTTGGACCAAGCTATGCAGGT-3 0 (forward) and 5 0 -AGAAGCGTTTGGCAATGTGC-3 0 (reverse) and the sequence-specific probe /HEX/5 0 -TTGGGATGACGCACTGCTGCATCAACCCCA-3 0 /ZenDQ. All qPCR reactions contained 25 ml AmpliTaq Gold PCR master mix (Applied Biosystems) in 50 ml reaction volume. Reaction mixtures were as previously described (Horwitz et al., 2013) . HIV-1 DNA is reported as copies per sample to CCR5 genomic copies per equivalent sample.
Terminal Graft
The presence of human lymphocytes at the terminal point was quantified from the spleen and PBMCs by flow cytometry. Isolation of PBMCs and splenocytes were as described above. Staining procedures were as described above.
Antibody Concentrations
Plasma levels of passively administered antibodies were quantified by two independent methods. gp120-specific ELISA was as previously described (Klein et al., 2012b) , using 10-1074 and 3BNC117 monoclonal antibodies as standard controls. The detection limit was 0.05 mg/ml. Because PG16 does not bind gp120 and endogenously produced gp120-reactive antibodies could confound the ELISA measurement, plasma antibody levels were also quantified by TZM-bl neutralization using the Tier 2 envelopes 3301.v1.c24 and YU2. A mixture with known amounts of 3BNC117, 10-1074, and PG16 was used as standard for calibration.
Day of Viral Rebound and Antibody Level at Rebound
Plasma viremias immediately preceding and following viral rebound were plotted on a semi-log-y axis versus days postinitial antibody injection (x axis) for each individual mouse. The linear portion of viremia was fit to a line by least-squares linear regression. The day that viremia crossed the 800 copies/ml quantitation limit, termed rebound day, was calculated from the viremia fit. The antibody concentrations (as determined by TZM-bl neutralization) spanning before and after viral rebound were plotted on a semi-log-y axis versus days postinitial antibody injection. The linear portion of antibody concentrations was fit to a line by least-squares linear regression, and the antibody concentration on the rebound day was calculated from the fit.
Antiretroviral Therapy
Individual tablets of tenofovir disproxil-fumarate (TDF; Gilead Sciences), emtricitabine (FTC; Gilead Sciences), and raltegravir (RAL; Merck) were crushed into fine powder and manufactured with TestDiet 5B1Q feed (Modified LabDiet 5058 with 0.12% amoxicillin) into 1/2'' irradiated pellets. Final concentrations of ART drugs in the food were 720 mg/kg TFV, 520 mg/kg FTC, and 4800 mg/kg RAL. Doses were chosen based on suppression of viremia in humanized mice as previously published (Denton et al., 2012; Nischang et al., 2012) and by pharmacokinetic analysis of these drugs in humanized mice (Roberto F. Speck, personal communication) . To test potential toxicity or reduced preference for drug-supplemented food, mice were weighed daily on normal diet and then switched to ART feed and weighed daily. There were no visible signs of toxicity, and mice maintained their weights. Assuming that mice weigh 25 g and eat 4 g of food per day, the drug doses correspond to 2.88 mg/kg TFV, 83 mg/kg FTC, and 768 mg/kg RAL daily.
Antibody Therapy
Plasmids encoding 10-1074 or PG16 heavy-and light-chain Ig genes were transfected into HEK293E cells. Antibodies were isolated from tissue-culture supernatant using Protein G Sepharose 4 Fast-Flow (GE Healthcare). Antibodies were then buffer exchanged into PBS and sterile filtered using Ultrafree-CL centrifugal filters (0.22 mm; Millipore). Endotoxin was removed from antibody preparations using Triton X-114 (Sigma-Aldrich) as previously described (Aida and Pabst, 1990) , and antibodies were concentrated to 10 mg/ml. Sterile, endotoxin-free 3BNC117 (20 mg/ml) was obtained from CellDex Therapeutics. All antibodies were injected subcutaneously as described.
Inducers Vorinostat (Selleckchem) was suspended in sterile water or sterile water plus 0.5% methylcellulose, 0.1% Tween (v/v) and administered by oral gavage at doses of 60 mg/kg (Krejsgaard et al., 2010) . For each mouse, three total doses were administered, spaced 48 hr apart. 100 mg doses of aCTLA4 were injected intraperitoneally (i.p.). Three total doses were administered, spaced 48 hr apart. I-BET 151 was obtained from GlaxoSmithKline and dissolved in 10% beta-cyclodextrin, 5% DMSO in 0.9% saline and injected daily for 14 days at doses of 30 mg/kg (Dawson et al., 2011) .
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0 for Mac OS X.
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